SCHEMBL21767228

SCHEMBL21767228

CCCC(CCCCNC(=O)CCCC(=O)ON1C(=O)CCC2CC21)C(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NAMPT P43490 1/20 0.31
MEN1 O00255 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC10 Q969S8 1/20 0.30
HDAC11 Q96DB2 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
HDAC9 Q9UKV0 1/20 0.30
HDAC5 Q9UQL6 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21767041 0.81 L3MBTL1 (0.37) L3MBTL1TSHRHSD17B10NAMPTCYP2C19
SCHEMBL20364047 0.72 NAMPT (0.38) L3MBTL1TSHRHSD17B10NAMPTCYP2C19
SCHEMBL19416301 0.68 NAMPT (0.41) L3MBTL1TSHRHSD17B10NAMPTMEN1
SCHEMBL21342633 0.68 HPGD (0.39) L3MBTL1TSHRHSD17B10NAMPTCYP2C19
SCHEMBL11990467 0.67 L3MBTL1 (0.50) L3MBTL1KMT2AHPGDHTTSMN1; SMN2
SCHEMBL18972339 0.66 L3MBTL1 (0.52) L3MBTL1KMT2AHPGDHTTSMN1; SMN2
SCHEMBL10140378 0.66 L3MBTL1 (0.52) L3MBTL1KMT2AHPGDHTTSMN1; SMN2
SCHEMBL24798238 0.65 HPGD (0.35) TSHRHSD17B10MEN1CYP2C19KMT2A
SCHEMBL19543157 0.65 L3MBTL1 (0.45) L3MBTL1TSHRKMT2AHPGDHTT
SCHEMBL20848172 0.65 SMN1; SMN2 (0.40) L3MBTL1TSHRHSD17B10NAMPTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067650-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. 2024-02-29 US disclosed
US-20200062757-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062757-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF TFRC, CLTC, SLC39A3 L3MBTL1 2999/4885TSHR 477/4885HSD17B10 4702/4885
US-20240067650-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF TFRC, CLTC, SLC39A3 L3MBTL1 2999/4885TSHR 477/4885HSD17B10 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.